$RXRX

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

Ark Invest, led by Cathie Wood, increased stakes in AI and biotech, buying $25.9M of CoreWeave, $24.4M of Meta, and $17.6M of Recursion. It also acquired $16.3M of Cerebras.

Recursion (RXRX) reported positive results from its Phase 1b/2 trial of REC-4881, showing an 87% mean reduction in GI polyp burden and a 92% reduction in upper GI. The drug demonstrated a favorable safety profile, with no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027, pending FDA discussions. Recursion had $561M in cash as of Sept 30, 2026, and expects $200M from a recent offering, extending its runway into 2029.

Zilow Group (Z) and Quantinuum (QNT) each rose 11.05%, while Recursion Pharmaceuticals (RXRX) and Telefonaktiebolaget LM Ericsson (ERIC) gained 11.23% and 11.87%, respectively. Kyndryl Holdings (KD) climbed 11.87% after a deal with Toyota Group. Zilow and peers benefited from falling Treasury yields, while Morgan Stanley upgraded Quantinuum with a 69% upside target. Recursion partnered with Sanofi, and Ericsson reported better-than-expected Q3 earnings.

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently p

Recursion Pharmaceuticals (RXRX) and Sanofi have collaborated to develop a potential first-in-class oral medicine for inflammatory diseases. Sanofi has optioned the first development candidate, triggering a milestone payment. The candidate is expected to enter phase 1 clinical trials in 2027, with Sanofi funding further development. Recursion's AI-enabled drug discovery platform was used in the development.

Recursion Pharmaceuticals (RXRX) priced a stock sale of 61.54 million shares at $3.25 per share, expected to raise about $200 million before costs. The offering includes participation from leading healthcare investors and is managed by Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore Group.

Recursion Pharmaceuticals (RXRX) announced positive Phase 1b/2 data for REC-4881, showing a 47% median reduction in polyp burden in FAP patients, with 85% maintaining reductions after 12 weeks off treatment. REC-1245 showed partial responses in cancer patients. Sanofi optioned a development candidate from their collaboration. The company raised $200M, extending its cash runway into 2029.

Recursion Pharmaceuticals Inc. (RXRX) shares fell 8.72% after bearish analyst coverage questioned its AI drug-discovery timeline. The company reported $7.3M in revenue and a $131M net loss for the quarter, with strong liquidity but high expenses. Traders are watching key price levels, with support around $3.70 and resistance near $4.80.

Insiders traded shares in five companies: Recursion Pharmaceuticals' CEO sold 25,000 shares, General Mills' segment president sold 6,294 shares, Star Bulk Carriers' director sold 6,000 shares, Berkshire Hathaway bought 2.42 million Lennar shares, and Hershey Trust sold 30,000 Hershey shares. These transactions may signal shifts in company outlooks.